Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Up 4.9%

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report)'s stock price traded up 4.9% during mid-day trading on Monday . The company traded as high as $25.26 and last traded at $25.26. 81,995 shares were traded during mid-day trading, a decline of 84% from the average session volume of 528,822 shares. The stock had previously closed at $24.07.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on MIRM shares. Morgan Stanley decreased their price target on shares of Mirum Pharmaceuticals from $57.00 to $53.00 and set an "overweight" rating for the company in a report on Friday, May 10th. SVB Leerink dropped their price objective on Mirum Pharmaceuticals from $44.00 to $43.00 and set an "outperform" rating for the company in a research note on Monday, March 18th. JMP Securities reduced their target price on shares of Mirum Pharmaceuticals from $72.00 to $66.00 and set a "market outperform" rating on the stock in a research note on Thursday, May 9th. Cantor Fitzgerald reiterated an "overweight" rating and set a $40.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, May 9th. Finally, HC Wainwright restated a "buy" rating and issued a $58.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 9th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $49.73.

Mirum Pharmaceuticals Price Performance

The company has a current ratio of 3.68, a quick ratio of 3.47 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -6.82 and a beta of 1.13. The company has a 50 day moving average price of $25.37 and a 200 day moving average price of $27.96.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its earnings results on Wednesday, February 28th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.32). The business had revenue of $69.55 million for the quarter, compared to analyst estimates of $66.73 million. Mirum Pharmaceuticals had a negative return on equity of 56.46% and a negative net margin of 69.67%. As a group, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.39 earnings per share for the current year.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 4,303 shares of the stock in a transaction on Monday, March 25th. The shares were sold at an average price of $25.80, for a total value of $111,017.40. Following the sale, the chief operating officer now directly owns 29,013 shares in the company, valued at $748,535.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, COO Peter Radovich sold 4,303 shares of the firm's stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $25.80, for a total transaction of $111,017.40. Following the sale, the chief operating officer now owns 29,013 shares of the company's stock, valued at $748,535.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Eric Bjerkholt bought 2,000 shares of the company's stock in a transaction on Wednesday, March 27th. The shares were bought at an average price of $24.80 per share, for a total transaction of $49,600.00. Following the completion of the acquisition, the chief financial officer now directly owns 14,000 shares in the company, valued at approximately $347,200. The disclosure for this purchase can be found here. Corporate insiders own 22.87% of the company's stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. grew its holdings in Mirum Pharmaceuticals by 0.4% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 6,495,392 shares of the company's stock worth $191,744,000 after purchasing an additional 25,000 shares during the period. Eventide Asset Management LLC boosted its stake in shares of Mirum Pharmaceuticals by 14.4% during the 3rd quarter. Eventide Asset Management LLC now owns 3,958,579 shares of the company's stock worth $125,091,000 after acquiring an additional 499,378 shares during the period. Janus Henderson Group PLC raised its stake in Mirum Pharmaceuticals by 34.2% in the 1st quarter. Janus Henderson Group PLC now owns 2,767,210 shares of the company's stock valued at $69,470,000 after acquiring an additional 704,659 shares during the period. Cadian Capital Management LP lifted its holdings in Mirum Pharmaceuticals by 34.8% during the 4th quarter. Cadian Capital Management LP now owns 1,934,922 shares of the company's stock valued at $57,119,000 after purchasing an additional 500,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Mirum Pharmaceuticals by 6.2% during the third quarter. Vanguard Group Inc. now owns 1,693,343 shares of the company's stock worth $53,510,000 after purchasing an additional 98,685 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.